Sarepta Therapeutics’ (SRPT) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $152.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the company. UBS Group increased their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a buy rating in a research report on Tuesday, September 17th. Bank of America increased their target price on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a research report on Friday, June 21st. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an overweight rating for the company in a report on Thursday, August 8th. BMO Capital Markets upped their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a research report on Monday, June 24th. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $181.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Three analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $187.39.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $127.21 on Friday. The stock has a market capitalization of $12.02 billion, a PE ratio of 1,156.45 and a beta of 0.81. The business’s fifty day moving average price is $137.26 and its 200 day moving average price is $132.75. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the firm posted ($0.27) EPS. Equities research analysts forecast that Sarepta Therapeutics will post 1.47 EPS for the current year.

Insider Buying and Selling

In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the company. Nordea Investment Management AB grew its position in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock worth $8,004,000 after acquiring an additional 33,711 shares in the last quarter. Capital Fund Management S.A. acquired a new position in Sarepta Therapeutics during the fourth quarter worth $7,299,000. ADAR1 Capital Management LLC bought a new position in Sarepta Therapeutics during the fourth quarter valued at about $777,000. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter worth about $607,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Sarepta Therapeutics by 125.3% during the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after acquiring an additional 27,549 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.